Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
Go to Page
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.
Copyright © 2016-2018 Drugdu.com. All Rights Reserved.